Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.

Automated summary

This report demonstrates a novel mutation, Q493R, of the SARS-CoV-2 spike protein that confers resistance to both bamlanivimab and etesivimab, isolated from a patient who had received treatment with these drugs.